Nebivolol 089pharm (Nebivolol)

Nebivolol selectively blocks β1‑adrenergic receptors, decreasing heart rate and contractility, which reduces cardiac output. It also enhances nitric‑oxide release from the endothelium, causing vasodilation of peripheral vessels. The combined effect lowers both systolic and diastolic blood pressure without significant β2 blockade.

The dosage of Nebivolol 089pharm is determined by the prescribing clinician based on the patient’s medical condition, age, renal function, and response to therapy. Physicians typically start with a low dose and titrate upward as needed to achieve target blood pressure or heart‑failure goals.

Safety data for nebivolol in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Nebivolol is a highly selective β1‑blocker with additional nitric‑oxide‑mediated vasodilation, which may result in fewer metabolic side effects and better tolerability compared with non‑selective beta‑blockers. Its dual mechanism can provide effective blood‑pressure control while preserving peripheral circulation.

Nebivolol 089pharm should be stored at room temperature, below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

Nebivolol 089pharm is taken orally, usually once daily with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their clinician and not alter the timing without medical advice.

Serious risks include severe bradycardia, marked hypotension, atrioventricular block, bronchospasm in patients with reactive airway disease, and rare allergic reactions such as anaphylaxis. Patients should seek immediate medical attention if they experience fainting, rapid heartbeat changes, difficulty breathing, or signs of an allergic response.

Nebivolol is contraindicated in patients with known hypersensitivity to nebivolol or any excipients, those with severe bradycardia, second‑ or third‑degree AV block without a pacemaker, cardiogenic shock, or uncontrolled heart failure. Caution is also advised for individuals with severe asthma or chronic obstructive pulmonary disease.